Surgical treatment of melanoma

British Journal of Dermatology

Volumn 149, Issue 1, 2003, Pages 2-12

  Eedy, D J ^a  

^a Royal Victoria Hospitals Trust   (United Kingdom)

Author keywords

Angiogenesis; Cutaneous malignant melanoma; Diagnostic imaging; Excision margins; Mohs' micrographic surgery; Positron emission tomography; Sentinel lymph nodes

Indexed keywords

ANGIOTENSIN; FIBROBLAST GROWTH FACTOR 2; GROWTH FACTOR; INTERLEUKIN 8; MELANIN; SELECTIN; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN C;

AMELANOTIC MELANOMA; ANGIOGENESIS; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHEMOSURGERY; CRYOTHERAPY; DERMATOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC IMAGING; EPILUMINESCENCE MICROSCOPY; ETHNIC GROUP; EXCISION; GENERAL PRACTITIONER; HISTORY; HUMAN; IMAGE ANALYSIS; LYMPH NODE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALIGNANT LENTIGO; MEDICAL PRACTICE; MEDICAL SPECIALIST; MELANOCYTE; MELANOMA; METASTASIS; MICROSURGERY; NEOVASCULARIZATION (PATHOLOGY); PARONYCHIA; PATIENT REFERRAL; PLASTIC SURGERY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PUNCH BIOPSY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; SKIN INCISION; SKIN METASTASIS; SKIN PIGMENTATION; STATISTICAL SIGNIFICANCE; SURGICAL TECHNIQUE; THICKNESS; TREATMENT OUTCOME; TUMOR BIOPSY; UNITED KINGDOM;

HUMANS; LYMPHATIC METASTASIS; MELANOMA; MOHS SURGERY; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0042635691     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.149.s64.8_65.x     Document Type: Review

References (118)

1. Davis NCO. William Norris MD.: a pioneer in the study of melanoma. Med J Aust 1980: 1: 52-4.
2. Handley WS. The pathology of melanotic growths in relation to their operative treatment. Lancet 1907: i: 927-33, 996-1003.
3. Roberts DLL, Anstey AV, Barlow RJ et al. U.K. guidelines for the management of cutaneous melanoma. Br J Dermatol 2002; 146: 7-17.
4. Ali FS, Harris PA, Butler PEM. Ambiguity in the U.K. guidelines for the management of cutaneous melanoma. Br J Dermatol 2002; 147: 835-6.
5. Newton-Bishop JA, Corrie PG, Evans J et al. Ambiguity in the U.K. guidelines for the management of cutaneous melanoma: reply from authors. Br J Dermatol 2002; 147: 836-7.
6. Russell-Jones R, Healy C, Calonje E et al. High-dose interferon and the U.K. guidelines for cutaneous melanoma. Br J Dermatol 2002: 147: 832-3.
7. Phillips WG. Sentinel lymph node biopsy and the U.K. guidelines for cutaneous melanoma. Br J Dermatol 2002; 147: 834 (Letter).
8. Newton-Bishop JA, Corrie PG, Evans J et al. Staging investigations and the U.K. guidelines for cutaneous melanoma: reply from authors. Br J Dermatol 2002: 147: 838 (Letter).
9. MacKie RM, Bray CA, Hole DJ. Observational study of the type of surgical training and outcome of definitive surgery for primary malignant melanoma. Br Med J 2002; 325: 1276-7.
10. Eedy DJ. Surgical training in treatment of cutaneous malignant melanoma. Br Med J Rapid responses online. http://www.bmj.com/cgi/letters/325/7325/1276#29315 1 February 2003.
11. Cassileth BR, Clark WH Jr, Lusk EJ et al. How well do physicians recognise melanoma and other problem lesions? J Am Acad Dermatol 1986; 14: 555-60.
12. Wayner RF Jr, Wagner D, Tomich JM et al. Diagnoses of skin disease: dermatologists vs non dermatologists. J Dermatol Surg Oncol 1985; 11: 476-9.
13. Ramsey DL, Fox AB. The ability of primary care physicians to recognise the common dermatoses. Arch Dermatol 1981; 117: 620-2.
14. Morton CA, MacKie RM. Clinical accuracy of the diagnosis of cutaneous malignant melanoma. Br J Dermatol 1998; 138: 283-7.
15. Williams HC, Smith D, du Vivier A. Melanoma. Differences observed by general surgeons and dermatologists. Int J Dermatol 1991; 30: 257-61.
16. Julian C. Dermatology in general practice. Br J Dermatol 1999; 141: 518-20.
17. Khorshid SM, Pinney E, Newton-Bishop JA. Melanoma excision by general practitioners in North-East Thames region, England. Br J Dermatol 1998; 138: 412-17.
18. English JSC. General practitioner excision of malignant melanoma. Br J Dermatol 1998; 139: 759 (Letter).
19. Eedy DJ. Non-melanoma skin cancer and the 'new National Health Service': implications for U.K. dermatology? Br J Dermatol 2000; 142: 397-400.
20. Carli P, De Giorgi V, Nardini P et al. Melanoma detection rate and concordance between self-skin examination and clinical evaluation in patients attending a pigmented lesion clinic in Italy. Br J Dermatol 2002; 146: 261-6.
21. Holme SA, Varma S, Chowdhury MMU, Roberts DLL. Audit of a melanoma screening day in the U.K.: clinical results, participant satisfaction and perceived value. Br J Dermatol 2001; 145: 784-8.
22. Osborne JE, Bourke JF, Holder J et al. The effect of the introduction of a pigmented lesion clinic on the interval between referral by family practitioner and attendance at hospital. Br J Dermatol 1998; 138: 418-21.
23. Osborne JE, Bourke JF, Graham-Brown RAC, Hutchinson PE. False negative clinical diagnoses of malignant melanoma. Br J Dermatol 1999; 140: 902-8.
24. Bataille V, Sasieni P, Curley RK et al. Melanoma yield, number of biopsies and missed melanomas in a British teaching hospital pigmented lesion clinic: a 9-year retrospective study. Br J Dermatol 1999; 140: 243-8.
25. MacKie RM, Fleming C, McMahon AD, Jarrett P. The use of the dermatoscope to identify early melanoma using the three-colour test. Br J Dermatol 2002; 146: 481-4.
26. Ascierto PA, Palmieri G, Celentano E et al. Sensitivity and specificity of epiluminescence microscopy: evaluation on a sample of 2731 excised cutaneous pigmented lesions. Br J Dermatol 2000; 142: 893-8.
27. Moncrieff M, Cotton S, Claridge E, Hall P. Spectrophotometric intracutaneous analysis: a new technique for imaging pigmented skin lesions. Br J Dermatol 2002; 146: 448-57.
28. Osborne JE, Chave TA, Hutchinson PE. Comparison of diagnostic accuracy for cutaneous malignant melanoma between a pigmented lesion clinic and other clinics. Br J Dermatol 2003; 148: 252-8.
29. Drummond A, Kane D, Bisland D. Legal claims in Scottish NHS Dermatology Departments 1989-2001. Br J Dermatol. 149: 111-14.
30. Swanson NA, Lee KL, Gorman A, Lee HN. Biopsy techniques: diagnosis of melanoma. Dermatol Clin 2002; 20: 677-80.
31. Lees VC, Briggs JC. Effect of initial biopsy procedure on prognosis in stage 1 invasive cutaneous malignant melanoma: review of 1086 patients. Br J Surg 1991; 78: 1108-10.
32. Bong JL, Herd RM, Hunter JA. Incisional biopsy and melanoma prognosis. J Am Acad Dermatol 2002; 46: 690-4.
33. Warr RP, Zebedee Z, Kenealy J et al. Detection of melanoma seeding during surgical procedures - an RT-PCR based model. Eur J Surg Oncol 2002; 28: 832-7.
34. Mahendran R, Newton-Bishop JA. Survey of U.K. current practice in the treatment of lentigo maligna. Br J Dermatol 2001; 144: 71-6.
35. Stephens G, Cockerell CJ. Avoid sampling error in the biopsy of pigmented lesions. Arch Dermatol 1996; 132: 1380-1.
36. Stomach SC, Taira JW, Pitha TV, Everett MA. Pigmented lesions in actinically damaged skin. Arch Dermatol 1996; 132: 1297-302.
37. Grande DJ, Koranda FC, Whittaker DC. Surgery of extensive, subclinical lentigo maligna. J Dermatol Surg Oncol 1982; 8: 493-6.
38. Barlow RD, White CR, Swanson NA. Mohs' micrographic surgery using frozen sections alone may be unsuitable for detecting single atypical melanocytes at the margins of melanoma in situ. Br J Dermatol 2002; 146: 290-4.
39. Fersht N, Spittle MF. Some aspects of radiotherapy for melanoma. Br J Dermatol 2001; 144: 1-2.
40. Schmid-Wendtner MH, Brunner B, Konz B et al. Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients. J Am Acad Dermatol 2000; 43: 477-82.
41. Panizzon RG. Die Röntgenweichstrahlentherapie als Alternative bei älteren Patienten. In: Onkologische Dermatologie (Burg G, Hartmann AA, Konz B, eds). Heidelberg: Springer-Verlag, 1992: 263-7.
42. Zalaudek I, Horn E, Richtig H et al. Local recurrence in melanoma in situ: influence of sex, age, site of involvement and therapeutic modalities. Br J Dermatol, 2003; 148: 703-8.
43. Shapiro RL. Surgical approaches to malignant melanoma. Practical guidelines. Dermatol Clin 2002; 20: 681-99.
44. Haneke E, Baran R. Longitudinal melanonychia. Dermatol Surg 2001; 27: 580-4.
45. McKenna DB, Lee RJ, Prescott RJ, Doherty VR. The time from diagnostic excision biopsy to wide local excision for primary cutaneous malignant melanoma may not affect patient survival. Br J Dermatol 2002; 147: 48-54.
46. Wong CK. A study of melanocytes in the normal skin surrounding malignant melanomata. Dermatologica 1970; 141: 215-25.
47. Fallowfield ME, Cook MG. Re-excisions of scar in primary cutaneous melanoma: a histopathological study. Br J Dermatol 1992; 126: 47-51.
48. Ackerman AB, Scheiner AM. How wide and deep is wide and deep enough? A critique of surgical practice in excisions of primary cutaneous malignant melanoma. Hum Pathol 1983: 14: 743-4.
49. Ackerman AB. Exploding myths about melanomal Dohi Memorial Lecture. J Dermatol 1999; 26: 702-5.
50. Ackerman AB. A centimeter here, a centimeter there. J Am Acad Dermatol 1996; 35: 279-80.
51. Kanzler MH, Swetter SM. Surgical margins for malignant melanoma: another point of view. J Am Acad Dermatol 1996; 35: 1014-15.
52. Martin HM, Birkin AJ, Theaker JM. Malignant melanoma reexcision specimens - how many blocks? Histopathology 1998; 32: 362-7.
53. Kirkham N. What is there to find in malignant melanoma reexcision specimens? Histopathology 1998; 32: 566-7.
54. Lens MB, Dawes M, Goodacre T, Newton-Bishop JA. Excision margins in the treatment of primary cutaneous melanoma. A systemic review of randomized controlled trials comparing narrow vs. wide excision. Arch Surg 2002; 137: 1101-5.
55. Zitelli JA, Brown C, Hanusa BH. Mohs' micrographic surgery for the treatment of primary cutaneous melanoma. J Am Acad Dermatol 1997; 37: 236-45.
56. Carucci JA. Mohs' micrographic surgery for the treatment of melanoma. Dermatol Clin 2002; 20: 701-8.
57. Nagi C, O'Grady TC, Izadpanah A. Mohs' micrographically controlled surgery and the treatment of malignant melanoma. Semin Oncol 2002; 29: 336-40.
58. Meier F, Will S, Ellwanger U et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 2002; 147: 62-70.
59. Eedy DJ. Updates from the British Association of Dermatologists 82nd Annual Meeting, 9-12 July 2002, Edinburgh, U.K. Br J Dermatol 2002; 147: 1080-95.
60. Fearfield L, Rowe A, Francis N et al. Prognostic factors in very thin melanoma. Br J Dermatol 2002; 147 (Suppl. 62): 14 (Abstr.).
61. Schmid-Wendtner MH, Baumert J, Eberle J et al. Disease progression in patients with thin cutaneous melanomas (tumour thickness ≤ 0.75 mm). Clinical and epidemiological data from the Tumour Center Munich 1977-1998. Br J Dermatol, in press.
62. Eve FA. Lecture on melanoma. Practitioner 1903; 70: 165-74.
63. Balch CM, Soong SJ, Bartolucci AA et al. Efficacy of an elective regional lymph node dissection of 1-4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996; 224: 255-63.
64. Casinelli N, Morabito A, Santinami M et al. Immediate or delayed dissection of regional lymph nodes in patients with melanoma of the trunk: a randomized trial. WHO melanoma programme. Lancet 1998; 351: 793-6.
65. Sim FH, Taylor WF, Ivins JC et al. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma: preliminary results. Cancer 1978; 41: 948-56.
66. Veronesi U, Adamus J, Bandiera DC et al. Inefficacy of immediate node dissection in stage I melanoma of the limbs. N Engl J Med 1977; 297: 627-30.
67. Pharis DB, Zitelli JA. The management of regional lymph nodes in cancer. Br J Dermatol, in press.
68. Stacker SA, Balwin ME, Achen MG. The role of tumour lymphangiogenesis in metastatic spread. FASEB J 2002; 16: 922-34.
69. Brandsma D, Reijneveld JC, Taphoorn MJD et al. Vascular cell adhesion molecule-1 is a key adhesion molecule in melanoma cell adhesion to leptomeninges. Lab Invest 2002; 82: 1493-502.
70. White RR, Stanley WE, Johnson JL et al. Long-term survival in 2505 patients with melanoma with regional lymph node metastases. Ann Surg 2002; 235: 879-87.
71. Morton DL, Wen DR, Wang JH et al. Technical details of intraoperative lymphatic mapping for early-stage melanoma. Arch Surg 1992; 127: 392-9.
72. Russell-Jones R, Acland KM. Sentinel node biopsy in the management of malignant melanoma. Clin Exp Dermatol 2001; 26: 463-8.
73. 18FDG PET imaging versus sentinel node detection. Oncologist 2002; 7: 271-8.
74. Balch CM, Soong SJ, Gershenwald JE et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 622-34.
75. Dessureault S, Soong SJ, Ross MI et al. American Joint Committee on Cancer (AJCC) Melanoma Staging Committee. Improved staging of node-negative patients with intermediate to thick melanomas (> 1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol 2001; 8: 749-51.
76. Balch CM, Soong SJ, Ross MI et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 cm to 4 cm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 2000; 7: 87-97.
77. Kirkwood JM, Ibrahim JG, Sosman JA et al. High-dose interferon alpha-2b significantly prolongs relapse-flee and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001; 19: 2370-80.
78. Wagner JD, Corbett L, Park HM. Sentinel lymph node biopsy for melanoma: experience with 234 consecutive procedures. Plast Reconstr Surg 2000; 105: 1956-66.
79. Jakub JW, Pendas S, Reintgen DS. Current status of sentinel lymph node mapping and biopsy: facts and controversies. Oncologist 2003; 8: 59-68.
80. Li W, Stall A, Shivers SC et al. Clinical relevance of molecular staging for melanoma: comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma. Ann Surg 2000; 231: 795-803.
81. Chao C, Wand GL, Ross MI et al. Patterns of early recurrence after sentinel lymph node biopsy for melanoma. Am J Surg 2002; 184: 520-5.
82. Blaheta H-J, Paul T, Sotlar K et al. Detection of melanoma cells in sentinel lymph nodes, bone marrow and peripheral blood by a reverse transcription-polymerase chain reaction assay in patients with primary cutaneous melanoma: association with Breslow's tumour thickness. Br J Dermatol 2001; 145: 195-202.
83. Russell-Jones R. The value of reverse transcription-polymerase chain reaction in malignant melanoma. Br J Dermatol 2001; 145: 193-4.
84. Goydos JS, Patel KN, Shih WJ et al. Patterns of recurrence in patients with melanoma and histologically negative but RT-PCR-positive sentinel lymph nodes. J Am Coll Surg 2003; 196: 196-204.
85. Longo MI, Lazaro P, Bueno C et al. Fluorodeoxyglucose-positron emission tomography imaging versus sentinel node biopsy in the primary staging of melanoma patients. Dermatol Surg 2003; 29: 245-8.
86. Thomé SD, Loprinzi CL. Heldebrant MP. Determination of potential adjuvant systemic therapy benefits for patients with resected cutaneous melanomas. Mayo Clin Proc 2002; 72: 913-17.
87. Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-48.
88. Reintgen DS, Cruse CW, Glass F, Fenske E. In support of sentinel lymph node biopsy as standard of care for patients with malignant melanoma. Dermatol Surg 2000; 26: 1070-2.
89. Anonymous News. WHO declares lymphatic mapping to be the standard of care for melanoma. Oncology 1999; 13: 288.
90. Connelly TJ. Regarding sentinel lymph node biopsy. Dermatol Surg 2001; 27: 425-6.
91. Connelly TJ. Lymphatic mapping and sentinel lymph node biopsy. J Am Acad Dermatol 2002; 46: 640.
92. Otley CC. Regarding sentinel node biopsy for melanoma - standard of care? Dermatol Surg 2000; 26: 1067-9.
93. Dubois RW, Swetter SM, Atkins M et al. Developing indications for the use of sentinel lymph node biopsy and adjuvant high-dose interferon alpha-2b in melanoma. Arch Dermatol 2001; 137: 1217-24.
94. Sober AJ, Chang T, Duvic M et al. Guidelines for the care for cutaneous melanoma. J Am Acad Dermatol 2001; 45: 579-86.
95. Medalie N, Ackerman AB. Sentinel lymph node biopsy has no benefit for patients with primary cutaneous melanoma: an assertion based on comprehensive critical analysis. Dermatopathol Pract Concept 2003; 9: 83-4.
96. Brountzos EN, Panagiotou IE, Bafaloukos DI, Kelekis DA. Ultrasonographic detection of regional lymph node metastases in patients with intermediate or thick malignant melanoma. Oncol Rep 2003; 10: 505-10.
97. Prichard RS, Hill ADK, Skehan SJ, O'Higgins NJ. Positron emission tomography for staging and management of malignant melanoma. Br J Surg 2002; 89: 389-96.
98. Boni R, Boni RA, Steinert H et al. Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose. Br J Dermatol 1995; 132: 556-62.
99. Rinne D, Baum RP, Horn G, Kaufmann R. Primary staging and follow up of high risk melanoma patients with whole body 18-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 1998; 82: 1664-71.
100. Acland KM, O'Doherty MJ, Russell-Jones R. The value of positron emission tomography scanning in the detection of subclinical metastatic melanoma. J Am Acad Dermatol 1999; 42: 606-11.
101. Holder WD, White RL, Zuger JH et al. Effectiveness of positron emission tomography for detection of melanoma metastases. Ann Surg 1998; 227: 764-9.
102. Shoaib T, Dunn R, Soutar DS. Staging investigations and the U.K. guidelines for cutaneous melanoma. Br J Dermatol 2002; 147: 837-8.
103. Finck SJ, Giuliano AE, Morton DL. LDH and melanoma. Cancer 1983; 51: 840-3.
104. Jury CS, McAllister EJ, MacKie RM. Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma. Br J Dermatol 2000; 143: 269-74.
105. Hauschild A, Engel G, Brenner W et al. Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Br J Dermatol 1999; 140: 1065-71.
106. Acland KM, Evans AV, Abraha H et al. Serum S100 concentrations are not useful in predicting micrometastatic disease in cutaneous malignant melanoma. Br J Dermatol 2002; 146: 832-5.
107. Hunzelmann N, Kurschat P, Hani N et al. Applicability of reference values for the determination of serum S100 protein as a marker of malignant melanoma in children. Br J Dermatol 2002; 146: 536-7.
108. Brochez L, Naeyaert J-M. Serological markers for melanoma. Br J Dermatol 2000; 143: 256-8.
109. Dicker TJ, Kavanagh GM, Herd RM et al. A rational melanoma follow-up in patients with primary cutaneous melanoma. Br J Dermatol 1999; 140: 249-54.
110. Rogers GS, Kopf AW, Rigel D et al. Hazard-rate analysis in stage 1 malignant melanoma. Arch Dermatol 1986; 122: 999-1002.
111. Williams HC. Follow-up for cutaneous malignant melanoma. Br J Dermatol 1999; 141: 762-3.
112. Romero JB, Stefanato CM, Kopf AW, Bart RS. Follow-up recommendations for patients with stage I malignant melanoma. J Dermatol Surg Oncol 1994; 20: 175-8.
113. Crowley NJ, Seigler HF. Late recurrence of malignant melanoma: analysis of 168 patients. Ann Surg 1990; 212: 713-17.
114. Callaway MP, Briggs JC. The incidence of late recurrence (greater than 10 years): an analysis of 536 consecutive cases of cutaneous melanoma. Br J Plast Surg 1989; 42: 46-9.
115. Schmidt-Wendtner MH, Baumert J, Schmidt M et al. Late metastases of cutaneous malignant melanoma: an analysis of 31 patients. J Am Acad Dermatol 2000; 43: 605-9.
116. Leman JA, MacKie RM. Late (> 10 years) recurrence of melanoma: the Scottish experience. Br J Dermatol 2003; 148: 372-3.
117. MacKie RM, Reid R, Junor B. Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N Engl J Med 2003; 348: 567-8.
118. Douglas JG, Margolin K. The treatment of brain metastases from malignant melanoma. Semin Oncol 2002; 29: 518-24.